OXiGENE Inc  

(Public, NASDAQ:OXGN)   Watch this stock  
Find more results for OXGN
2.19
-0.07 (-3.10%)
Real-time:   3:43PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.18 - 2.30
52 week 1.96 - 5.40
Open 2.29
Vol / Avg. 459,813.00/316,221.00
Mkt cap 45.55M
P/E     -
Div/yield     -
EPS -3.03
Shares 20.71M
Beta 2.07
Inst. own 23%
Nov 12, 2014
Q3 2014 OXiGENE, Inc. Earnings Conference Call - 4:30PM EST - Add to calendar
Nov 12, 2014
Q3 2014 OXiGENE Inc Earnings Release - 4:00PM EST - Add to calendar
Sep 9, 2014
OXiGENE Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -8712.63%
Operating margin - -8715.79%
EBITD margin - -8600.00%
Return on average assets -50.76% -129.93%
Return on average equity -53.65% -246.97%
Employees 9 -
CDP Score - -

Address

Suite 210, 701 Gateway Blvd
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-6357000 (Phone)
+1-650-6357001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

OXiGENE, Inc. is a clinical-stage, biopharmaceutical company developing novel therapeutics primarily to treat cancer. The Company primary focus is the development of product candidates referred to as vascular disrupting agents (VDAs), that selectively disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival, and also are associated with visual impairment in a number of ophthalmological diseases and conditions. The Company�s lead compound, ZYBRESTAT is a reversible tubulin binding agent that works by disrupting the network of abnormal blood vessels, or vasculature, within solid tumors, also referred to as vascular disruption. The Company is pursuing development of OXi4503, a second-generation, dual-mechanism VDA, as a treatment for certain solid tumor types and for the treatment of myeloid leukemias, which also represent orphan indications.

Officers and directors

Frederick W. Driscoll Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
David Chaplin Ph.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Barbara Riching Chief Financial Officer, Vice President
Age: 55
Bio & Compensation  - Reuters
Tamar D. Howson Independent Director
Age: 65
Bio & Compensation  - Reuters
Gerald McMahon Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
William D. Schwieterman M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters